Research ArticleArticle
Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study
Kazuki Yoshida, Helga Radner, Maria D. Mjaavatten, Jeffrey D. Greenberg, Arthur Kavanaugh, Mitsumasa Kishimoto, Kazuo Matsui, Masato Okada, George Reed, Yukihiko Saeki, Shigeto Tohma, Joel Kremer and Daniel H. Solomon
The Journal of Rheumatology November 2015, jrheum.150240; DOI: https://doi.org/10.3899/jrheum.150240
Kazuki Yoshida
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston; University of Massachusetts Medical School, Worcester, Massachusetts; New York University Hospital for Joint Diseases, New York; Albany Medical College, Center for Rheumatology, Albany, New York; Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California, USA; Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo; Department of Rheumatology, Kameda Medical Center, Kamogawa; Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka; Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. This study was conducted entirely independently of any pharmaceutical company input. NinJa has been supported in part by a Health and Labor Sciences Research Grant from the Ministry of Health, Labor, and Welfare of Japan. KY receives tuition support jointly from Japan Student Services Organization and Harvard T.H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer, and PhRMA). JDG is an employee and shareholder of CORRONA. He has received consulting fees from AstraZeneca and Pfizer. AK has conducted sponsored clinical research for Amgen and UCB. MK received speaking fees and/or honoraria from Pfizer. MO received speaking fees and/or honoraria from Pfizer. GR is an employee of CORRONA. ST received research grants from Pfizer Japan Inc. JK received research grants from Amgen, Genentech, Pfizer, and UCB. He owns shares in CORRONA and derives salary support. DHS receives salary support from institutional research grants from Eli Lilly, Amgen, and CORRONA. He also serves in unpaid roles in studies funded by Pfizer and Eli Lilly, and receives salary support from NIH-K24AR055989. K. Yoshida, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Epidemiology, Harvard T.H. Chan School of Public Health; H. Radner, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna; M.D. Mjaavatten, MD, PhD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Rheumatology, Diakonhjemmet Hospital; J.D. Greenberg, MD, MPH, New York University Hospital for Joint Diseases; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California San Diego; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital; K. Matsui, MD, Department of Rheumatology, Kameda Medical Center; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital; G. Reed, PhD, University of Massachusetts Medical School; Y. Saeki, MD, PhD, Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center; S. Tohma, MD, Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital; J. Kremer, MD, Albany Medical College, Center for Rheumatology; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. K. Yoshida, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis St., Boston, Massachusetts 02115, USA. E-mail: kazukiyoshida@mail.harvard.edu. Accepted for publication August 11, 2015.
Helga Radner
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston; University of Massachusetts Medical School, Worcester, Massachusetts; New York University Hospital for Joint Diseases, New York; Albany Medical College, Center for Rheumatology, Albany, New York; Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California, USA; Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo; Department of Rheumatology, Kameda Medical Center, Kamogawa; Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka; Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. This study was conducted entirely independently of any pharmaceutical company input. NinJa has been supported in part by a Health and Labor Sciences Research Grant from the Ministry of Health, Labor, and Welfare of Japan. KY receives tuition support jointly from Japan Student Services Organization and Harvard T.H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer, and PhRMA). JDG is an employee and shareholder of CORRONA. He has received consulting fees from AstraZeneca and Pfizer. AK has conducted sponsored clinical research for Amgen and UCB. MK received speaking fees and/or honoraria from Pfizer. MO received speaking fees and/or honoraria from Pfizer. GR is an employee of CORRONA. ST received research grants from Pfizer Japan Inc. JK received research grants from Amgen, Genentech, Pfizer, and UCB. He owns shares in CORRONA and derives salary support. DHS receives salary support from institutional research grants from Eli Lilly, Amgen, and CORRONA. He also serves in unpaid roles in studies funded by Pfizer and Eli Lilly, and receives salary support from NIH-K24AR055989. K. Yoshida, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Epidemiology, Harvard T.H. Chan School of Public Health; H. Radner, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna; M.D. Mjaavatten, MD, PhD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Rheumatology, Diakonhjemmet Hospital; J.D. Greenberg, MD, MPH, New York University Hospital for Joint Diseases; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California San Diego; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital; K. Matsui, MD, Department of Rheumatology, Kameda Medical Center; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital; G. Reed, PhD, University of Massachusetts Medical School; Y. Saeki, MD, PhD, Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center; S. Tohma, MD, Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital; J. Kremer, MD, Albany Medical College, Center for Rheumatology; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. K. Yoshida, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis St., Boston, Massachusetts 02115, USA. E-mail: kazukiyoshida@mail.harvard.edu. Accepted for publication August 11, 2015.
Maria D. Mjaavatten
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston; University of Massachusetts Medical School, Worcester, Massachusetts; New York University Hospital for Joint Diseases, New York; Albany Medical College, Center for Rheumatology, Albany, New York; Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California, USA; Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo; Department of Rheumatology, Kameda Medical Center, Kamogawa; Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka; Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. This study was conducted entirely independently of any pharmaceutical company input. NinJa has been supported in part by a Health and Labor Sciences Research Grant from the Ministry of Health, Labor, and Welfare of Japan. KY receives tuition support jointly from Japan Student Services Organization and Harvard T.H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer, and PhRMA). JDG is an employee and shareholder of CORRONA. He has received consulting fees from AstraZeneca and Pfizer. AK has conducted sponsored clinical research for Amgen and UCB. MK received speaking fees and/or honoraria from Pfizer. MO received speaking fees and/or honoraria from Pfizer. GR is an employee of CORRONA. ST received research grants from Pfizer Japan Inc. JK received research grants from Amgen, Genentech, Pfizer, and UCB. He owns shares in CORRONA and derives salary support. DHS receives salary support from institutional research grants from Eli Lilly, Amgen, and CORRONA. He also serves in unpaid roles in studies funded by Pfizer and Eli Lilly, and receives salary support from NIH-K24AR055989. K. Yoshida, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Epidemiology, Harvard T.H. Chan School of Public Health; H. Radner, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna; M.D. Mjaavatten, MD, PhD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Rheumatology, Diakonhjemmet Hospital; J.D. Greenberg, MD, MPH, New York University Hospital for Joint Diseases; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California San Diego; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital; K. Matsui, MD, Department of Rheumatology, Kameda Medical Center; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital; G. Reed, PhD, University of Massachusetts Medical School; Y. Saeki, MD, PhD, Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center; S. Tohma, MD, Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital; J. Kremer, MD, Albany Medical College, Center for Rheumatology; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. K. Yoshida, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis St., Boston, Massachusetts 02115, USA. E-mail: kazukiyoshida@mail.harvard.edu. Accepted for publication August 11, 2015.
Jeffrey D. Greenberg
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston; University of Massachusetts Medical School, Worcester, Massachusetts; New York University Hospital for Joint Diseases, New York; Albany Medical College, Center for Rheumatology, Albany, New York; Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California, USA; Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo; Department of Rheumatology, Kameda Medical Center, Kamogawa; Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka; Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. This study was conducted entirely independently of any pharmaceutical company input. NinJa has been supported in part by a Health and Labor Sciences Research Grant from the Ministry of Health, Labor, and Welfare of Japan. KY receives tuition support jointly from Japan Student Services Organization and Harvard T.H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer, and PhRMA). JDG is an employee and shareholder of CORRONA. He has received consulting fees from AstraZeneca and Pfizer. AK has conducted sponsored clinical research for Amgen and UCB. MK received speaking fees and/or honoraria from Pfizer. MO received speaking fees and/or honoraria from Pfizer. GR is an employee of CORRONA. ST received research grants from Pfizer Japan Inc. JK received research grants from Amgen, Genentech, Pfizer, and UCB. He owns shares in CORRONA and derives salary support. DHS receives salary support from institutional research grants from Eli Lilly, Amgen, and CORRONA. He also serves in unpaid roles in studies funded by Pfizer and Eli Lilly, and receives salary support from NIH-K24AR055989. K. Yoshida, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Epidemiology, Harvard T.H. Chan School of Public Health; H. Radner, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna; M.D. Mjaavatten, MD, PhD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Rheumatology, Diakonhjemmet Hospital; J.D. Greenberg, MD, MPH, New York University Hospital for Joint Diseases; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California San Diego; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital; K. Matsui, MD, Department of Rheumatology, Kameda Medical Center; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital; G. Reed, PhD, University of Massachusetts Medical School; Y. Saeki, MD, PhD, Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center; S. Tohma, MD, Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital; J. Kremer, MD, Albany Medical College, Center for Rheumatology; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. K. Yoshida, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis St., Boston, Massachusetts 02115, USA. E-mail: kazukiyoshida@mail.harvard.edu. Accepted for publication August 11, 2015.
Arthur Kavanaugh
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston; University of Massachusetts Medical School, Worcester, Massachusetts; New York University Hospital for Joint Diseases, New York; Albany Medical College, Center for Rheumatology, Albany, New York; Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California, USA; Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo; Department of Rheumatology, Kameda Medical Center, Kamogawa; Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka; Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. This study was conducted entirely independently of any pharmaceutical company input. NinJa has been supported in part by a Health and Labor Sciences Research Grant from the Ministry of Health, Labor, and Welfare of Japan. KY receives tuition support jointly from Japan Student Services Organization and Harvard T.H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer, and PhRMA). JDG is an employee and shareholder of CORRONA. He has received consulting fees from AstraZeneca and Pfizer. AK has conducted sponsored clinical research for Amgen and UCB. MK received speaking fees and/or honoraria from Pfizer. MO received speaking fees and/or honoraria from Pfizer. GR is an employee of CORRONA. ST received research grants from Pfizer Japan Inc. JK received research grants from Amgen, Genentech, Pfizer, and UCB. He owns shares in CORRONA and derives salary support. DHS receives salary support from institutional research grants from Eli Lilly, Amgen, and CORRONA. He also serves in unpaid roles in studies funded by Pfizer and Eli Lilly, and receives salary support from NIH-K24AR055989. K. Yoshida, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Epidemiology, Harvard T.H. Chan School of Public Health; H. Radner, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna; M.D. Mjaavatten, MD, PhD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Rheumatology, Diakonhjemmet Hospital; J.D. Greenberg, MD, MPH, New York University Hospital for Joint Diseases; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California San Diego; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital; K. Matsui, MD, Department of Rheumatology, Kameda Medical Center; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital; G. Reed, PhD, University of Massachusetts Medical School; Y. Saeki, MD, PhD, Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center; S. Tohma, MD, Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital; J. Kremer, MD, Albany Medical College, Center for Rheumatology; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. K. Yoshida, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis St., Boston, Massachusetts 02115, USA. E-mail: kazukiyoshida@mail.harvard.edu. Accepted for publication August 11, 2015.
Mitsumasa Kishimoto
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston; University of Massachusetts Medical School, Worcester, Massachusetts; New York University Hospital for Joint Diseases, New York; Albany Medical College, Center for Rheumatology, Albany, New York; Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California, USA; Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo; Department of Rheumatology, Kameda Medical Center, Kamogawa; Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka; Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. This study was conducted entirely independently of any pharmaceutical company input. NinJa has been supported in part by a Health and Labor Sciences Research Grant from the Ministry of Health, Labor, and Welfare of Japan. KY receives tuition support jointly from Japan Student Services Organization and Harvard T.H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer, and PhRMA). JDG is an employee and shareholder of CORRONA. He has received consulting fees from AstraZeneca and Pfizer. AK has conducted sponsored clinical research for Amgen and UCB. MK received speaking fees and/or honoraria from Pfizer. MO received speaking fees and/or honoraria from Pfizer. GR is an employee of CORRONA. ST received research grants from Pfizer Japan Inc. JK received research grants from Amgen, Genentech, Pfizer, and UCB. He owns shares in CORRONA and derives salary support. DHS receives salary support from institutional research grants from Eli Lilly, Amgen, and CORRONA. He also serves in unpaid roles in studies funded by Pfizer and Eli Lilly, and receives salary support from NIH-K24AR055989. K. Yoshida, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Epidemiology, Harvard T.H. Chan School of Public Health; H. Radner, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna; M.D. Mjaavatten, MD, PhD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Rheumatology, Diakonhjemmet Hospital; J.D. Greenberg, MD, MPH, New York University Hospital for Joint Diseases; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California San Diego; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital; K. Matsui, MD, Department of Rheumatology, Kameda Medical Center; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital; G. Reed, PhD, University of Massachusetts Medical School; Y. Saeki, MD, PhD, Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center; S. Tohma, MD, Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital; J. Kremer, MD, Albany Medical College, Center for Rheumatology; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. K. Yoshida, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis St., Boston, Massachusetts 02115, USA. E-mail: kazukiyoshida@mail.harvard.edu. Accepted for publication August 11, 2015.
Kazuo Matsui
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston; University of Massachusetts Medical School, Worcester, Massachusetts; New York University Hospital for Joint Diseases, New York; Albany Medical College, Center for Rheumatology, Albany, New York; Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California, USA; Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo; Department of Rheumatology, Kameda Medical Center, Kamogawa; Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka; Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. This study was conducted entirely independently of any pharmaceutical company input. NinJa has been supported in part by a Health and Labor Sciences Research Grant from the Ministry of Health, Labor, and Welfare of Japan. KY receives tuition support jointly from Japan Student Services Organization and Harvard T.H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer, and PhRMA). JDG is an employee and shareholder of CORRONA. He has received consulting fees from AstraZeneca and Pfizer. AK has conducted sponsored clinical research for Amgen and UCB. MK received speaking fees and/or honoraria from Pfizer. MO received speaking fees and/or honoraria from Pfizer. GR is an employee of CORRONA. ST received research grants from Pfizer Japan Inc. JK received research grants from Amgen, Genentech, Pfizer, and UCB. He owns shares in CORRONA and derives salary support. DHS receives salary support from institutional research grants from Eli Lilly, Amgen, and CORRONA. He also serves in unpaid roles in studies funded by Pfizer and Eli Lilly, and receives salary support from NIH-K24AR055989. K. Yoshida, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Epidemiology, Harvard T.H. Chan School of Public Health; H. Radner, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna; M.D. Mjaavatten, MD, PhD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Rheumatology, Diakonhjemmet Hospital; J.D. Greenberg, MD, MPH, New York University Hospital for Joint Diseases; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California San Diego; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital; K. Matsui, MD, Department of Rheumatology, Kameda Medical Center; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital; G. Reed, PhD, University of Massachusetts Medical School; Y. Saeki, MD, PhD, Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center; S. Tohma, MD, Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital; J. Kremer, MD, Albany Medical College, Center for Rheumatology; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. K. Yoshida, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis St., Boston, Massachusetts 02115, USA. E-mail: kazukiyoshida@mail.harvard.edu. Accepted for publication August 11, 2015.
Masato Okada
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston; University of Massachusetts Medical School, Worcester, Massachusetts; New York University Hospital for Joint Diseases, New York; Albany Medical College, Center for Rheumatology, Albany, New York; Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California, USA; Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo; Department of Rheumatology, Kameda Medical Center, Kamogawa; Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka; Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. This study was conducted entirely independently of any pharmaceutical company input. NinJa has been supported in part by a Health and Labor Sciences Research Grant from the Ministry of Health, Labor, and Welfare of Japan. KY receives tuition support jointly from Japan Student Services Organization and Harvard T.H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer, and PhRMA). JDG is an employee and shareholder of CORRONA. He has received consulting fees from AstraZeneca and Pfizer. AK has conducted sponsored clinical research for Amgen and UCB. MK received speaking fees and/or honoraria from Pfizer. MO received speaking fees and/or honoraria from Pfizer. GR is an employee of CORRONA. ST received research grants from Pfizer Japan Inc. JK received research grants from Amgen, Genentech, Pfizer, and UCB. He owns shares in CORRONA and derives salary support. DHS receives salary support from institutional research grants from Eli Lilly, Amgen, and CORRONA. He also serves in unpaid roles in studies funded by Pfizer and Eli Lilly, and receives salary support from NIH-K24AR055989. K. Yoshida, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Epidemiology, Harvard T.H. Chan School of Public Health; H. Radner, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna; M.D. Mjaavatten, MD, PhD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Rheumatology, Diakonhjemmet Hospital; J.D. Greenberg, MD, MPH, New York University Hospital for Joint Diseases; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California San Diego; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital; K. Matsui, MD, Department of Rheumatology, Kameda Medical Center; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital; G. Reed, PhD, University of Massachusetts Medical School; Y. Saeki, MD, PhD, Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center; S. Tohma, MD, Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital; J. Kremer, MD, Albany Medical College, Center for Rheumatology; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. K. Yoshida, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis St., Boston, Massachusetts 02115, USA. E-mail: kazukiyoshida@mail.harvard.edu. Accepted for publication August 11, 2015.
George Reed
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston; University of Massachusetts Medical School, Worcester, Massachusetts; New York University Hospital for Joint Diseases, New York; Albany Medical College, Center for Rheumatology, Albany, New York; Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California, USA; Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo; Department of Rheumatology, Kameda Medical Center, Kamogawa; Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka; Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. This study was conducted entirely independently of any pharmaceutical company input. NinJa has been supported in part by a Health and Labor Sciences Research Grant from the Ministry of Health, Labor, and Welfare of Japan. KY receives tuition support jointly from Japan Student Services Organization and Harvard T.H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer, and PhRMA). JDG is an employee and shareholder of CORRONA. He has received consulting fees from AstraZeneca and Pfizer. AK has conducted sponsored clinical research for Amgen and UCB. MK received speaking fees and/or honoraria from Pfizer. MO received speaking fees and/or honoraria from Pfizer. GR is an employee of CORRONA. ST received research grants from Pfizer Japan Inc. JK received research grants from Amgen, Genentech, Pfizer, and UCB. He owns shares in CORRONA and derives salary support. DHS receives salary support from institutional research grants from Eli Lilly, Amgen, and CORRONA. He also serves in unpaid roles in studies funded by Pfizer and Eli Lilly, and receives salary support from NIH-K24AR055989. K. Yoshida, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Epidemiology, Harvard T.H. Chan School of Public Health; H. Radner, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna; M.D. Mjaavatten, MD, PhD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Rheumatology, Diakonhjemmet Hospital; J.D. Greenberg, MD, MPH, New York University Hospital for Joint Diseases; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California San Diego; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital; K. Matsui, MD, Department of Rheumatology, Kameda Medical Center; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital; G. Reed, PhD, University of Massachusetts Medical School; Y. Saeki, MD, PhD, Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center; S. Tohma, MD, Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital; J. Kremer, MD, Albany Medical College, Center for Rheumatology; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. K. Yoshida, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis St., Boston, Massachusetts 02115, USA. E-mail: kazukiyoshida@mail.harvard.edu. Accepted for publication August 11, 2015.
Yukihiko Saeki
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston; University of Massachusetts Medical School, Worcester, Massachusetts; New York University Hospital for Joint Diseases, New York; Albany Medical College, Center for Rheumatology, Albany, New York; Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California, USA; Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo; Department of Rheumatology, Kameda Medical Center, Kamogawa; Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka; Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. This study was conducted entirely independently of any pharmaceutical company input. NinJa has been supported in part by a Health and Labor Sciences Research Grant from the Ministry of Health, Labor, and Welfare of Japan. KY receives tuition support jointly from Japan Student Services Organization and Harvard T.H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer, and PhRMA). JDG is an employee and shareholder of CORRONA. He has received consulting fees from AstraZeneca and Pfizer. AK has conducted sponsored clinical research for Amgen and UCB. MK received speaking fees and/or honoraria from Pfizer. MO received speaking fees and/or honoraria from Pfizer. GR is an employee of CORRONA. ST received research grants from Pfizer Japan Inc. JK received research grants from Amgen, Genentech, Pfizer, and UCB. He owns shares in CORRONA and derives salary support. DHS receives salary support from institutional research grants from Eli Lilly, Amgen, and CORRONA. He also serves in unpaid roles in studies funded by Pfizer and Eli Lilly, and receives salary support from NIH-K24AR055989. K. Yoshida, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Epidemiology, Harvard T.H. Chan School of Public Health; H. Radner, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna; M.D. Mjaavatten, MD, PhD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Rheumatology, Diakonhjemmet Hospital; J.D. Greenberg, MD, MPH, New York University Hospital for Joint Diseases; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California San Diego; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital; K. Matsui, MD, Department of Rheumatology, Kameda Medical Center; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital; G. Reed, PhD, University of Massachusetts Medical School; Y. Saeki, MD, PhD, Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center; S. Tohma, MD, Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital; J. Kremer, MD, Albany Medical College, Center for Rheumatology; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. K. Yoshida, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis St., Boston, Massachusetts 02115, USA. E-mail: kazukiyoshida@mail.harvard.edu. Accepted for publication August 11, 2015.
Shigeto Tohma
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston; University of Massachusetts Medical School, Worcester, Massachusetts; New York University Hospital for Joint Diseases, New York; Albany Medical College, Center for Rheumatology, Albany, New York; Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California, USA; Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo; Department of Rheumatology, Kameda Medical Center, Kamogawa; Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka; Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. This study was conducted entirely independently of any pharmaceutical company input. NinJa has been supported in part by a Health and Labor Sciences Research Grant from the Ministry of Health, Labor, and Welfare of Japan. KY receives tuition support jointly from Japan Student Services Organization and Harvard T.H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer, and PhRMA). JDG is an employee and shareholder of CORRONA. He has received consulting fees from AstraZeneca and Pfizer. AK has conducted sponsored clinical research for Amgen and UCB. MK received speaking fees and/or honoraria from Pfizer. MO received speaking fees and/or honoraria from Pfizer. GR is an employee of CORRONA. ST received research grants from Pfizer Japan Inc. JK received research grants from Amgen, Genentech, Pfizer, and UCB. He owns shares in CORRONA and derives salary support. DHS receives salary support from institutional research grants from Eli Lilly, Amgen, and CORRONA. He also serves in unpaid roles in studies funded by Pfizer and Eli Lilly, and receives salary support from NIH-K24AR055989. K. Yoshida, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Epidemiology, Harvard T.H. Chan School of Public Health; H. Radner, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna; M.D. Mjaavatten, MD, PhD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Rheumatology, Diakonhjemmet Hospital; J.D. Greenberg, MD, MPH, New York University Hospital for Joint Diseases; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California San Diego; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital; K. Matsui, MD, Department of Rheumatology, Kameda Medical Center; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital; G. Reed, PhD, University of Massachusetts Medical School; Y. Saeki, MD, PhD, Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center; S. Tohma, MD, Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital; J. Kremer, MD, Albany Medical College, Center for Rheumatology; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. K. Yoshida, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis St., Boston, Massachusetts 02115, USA. E-mail: kazukiyoshida@mail.harvard.edu. Accepted for publication August 11, 2015.
Joel Kremer
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston; University of Massachusetts Medical School, Worcester, Massachusetts; New York University Hospital for Joint Diseases, New York; Albany Medical College, Center for Rheumatology, Albany, New York; Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California, USA; Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo; Department of Rheumatology, Kameda Medical Center, Kamogawa; Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka; Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. This study was conducted entirely independently of any pharmaceutical company input. NinJa has been supported in part by a Health and Labor Sciences Research Grant from the Ministry of Health, Labor, and Welfare of Japan. KY receives tuition support jointly from Japan Student Services Organization and Harvard T.H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer, and PhRMA). JDG is an employee and shareholder of CORRONA. He has received consulting fees from AstraZeneca and Pfizer. AK has conducted sponsored clinical research for Amgen and UCB. MK received speaking fees and/or honoraria from Pfizer. MO received speaking fees and/or honoraria from Pfizer. GR is an employee of CORRONA. ST received research grants from Pfizer Japan Inc. JK received research grants from Amgen, Genentech, Pfizer, and UCB. He owns shares in CORRONA and derives salary support. DHS receives salary support from institutional research grants from Eli Lilly, Amgen, and CORRONA. He also serves in unpaid roles in studies funded by Pfizer and Eli Lilly, and receives salary support from NIH-K24AR055989. K. Yoshida, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Epidemiology, Harvard T.H. Chan School of Public Health; H. Radner, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna; M.D. Mjaavatten, MD, PhD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Rheumatology, Diakonhjemmet Hospital; J.D. Greenberg, MD, MPH, New York University Hospital for Joint Diseases; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California San Diego; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital; K. Matsui, MD, Department of Rheumatology, Kameda Medical Center; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital; G. Reed, PhD, University of Massachusetts Medical School; Y. Saeki, MD, PhD, Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center; S. Tohma, MD, Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital; J. Kremer, MD, Albany Medical College, Center for Rheumatology; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. K. Yoshida, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis St., Boston, Massachusetts 02115, USA. E-mail: kazukiyoshida@mail.harvard.edu. Accepted for publication August 11, 2015.
Daniel H. Solomon
From the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston; University of Massachusetts Medical School, Worcester, Massachusetts; New York University Hospital for Joint Diseases, New York; Albany Medical College, Center for Rheumatology, Albany, New York; Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California, USA; Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo; Department of Rheumatology, Kameda Medical Center, Kamogawa; Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka; Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan. The CORRONA Rheumatoid Arthritis registry has been supported through contracted subscriptions in the last 2 years by Abbvie, Amgen, AstraZeneca, Genentech, Horizon Pharma, Eli Lilly, Novartis, Pfizer, Vertex, and UCB. This study was conducted entirely independently of any pharmaceutical company input. NinJa has been supported in part by a Health and Labor Sciences Research Grant from the Ministry of Health, Labor, and Welfare of Japan. KY receives tuition support jointly from Japan Student Services Organization and Harvard T.H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer, and PhRMA). JDG is an employee and shareholder of CORRONA. He has received consulting fees from AstraZeneca and Pfizer. AK has conducted sponsored clinical research for Amgen and UCB. MK received speaking fees and/or honoraria from Pfizer. MO received speaking fees and/or honoraria from Pfizer. GR is an employee of CORRONA. ST received research grants from Pfizer Japan Inc. JK received research grants from Amgen, Genentech, Pfizer, and UCB. He owns shares in CORRONA and derives salary support. DHS receives salary support from institutional research grants from Eli Lilly, Amgen, and CORRONA. He also serves in unpaid roles in studies funded by Pfizer and Eli Lilly, and receives salary support from NIH-K24AR055989. K. Yoshida, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Epidemiology, Harvard T.H. Chan School of Public Health; H. Radner, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna; M.D. Mjaavatten, MD, PhD, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, and Department of Rheumatology, Diakonhjemmet Hospital; J.D. Greenberg, MD, MPH, New York University Hospital for Joint Diseases; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California San Diego; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital; K. Matsui, MD, Department of Rheumatology, Kameda Medical Center; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital; G. Reed, PhD, University of Massachusetts Medical School; Y. Saeki, MD, PhD, Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center; S. Tohma, MD, Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital; J. Kremer, MD, Albany Medical College, Center for Rheumatology; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. K. Yoshida, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis St., Boston, Massachusetts 02115, USA. E-mail: kazukiyoshida@mail.harvard.edu. Accepted for publication August 11, 2015.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study
Kazuki Yoshida, Helga Radner, Maria D. Mjaavatten, Jeffrey D. Greenberg, Arthur Kavanaugh, Mitsumasa Kishimoto, Kazuo Matsui, Masato Okada, George Reed, Yukihiko Saeki, Shigeto Tohma, Joel Kremer, Daniel H. Solomon
The Journal of Rheumatology Nov 2015, jrheum.150240; DOI: 10.3899/jrheum.150240
Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study
Kazuki Yoshida, Helga Radner, Maria D. Mjaavatten, Jeffrey D. Greenberg, Arthur Kavanaugh, Mitsumasa Kishimoto, Kazuo Matsui, Masato Okada, George Reed, Yukihiko Saeki, Shigeto Tohma, Joel Kremer, Daniel H. Solomon
The Journal of Rheumatology Nov 2015, jrheum.150240; DOI: 10.3899/jrheum.150240